Positive impact of the antimicrobial drug on survival and recuperation times in patients with covid 19

Case Report Positive Impact of the antimicrobial drug on Survival and Recuperation Times in Patients with COVID-19. Meronica A Warney Department of Respiratory Medicine, St Helier University Hospital, UK. *Corresponding Author : Meronica A Warney, Department of Respiratory Medicine, St Helier University Hospital, UK. Received : October 28, 2023 Accepted: October 29, 2023 Published : November 29, 2023 Abstract

Few papers that describe the diagnostic performance of serological tests for Campylobacter spp. were found in our search of the literature. Just 13 papers were chosen for examination out of the 133 that were found using manual searches and databases. These papers primarily describe the outcomes of serological tests using complement fixation, immunochromatography, and enzyme immunoassay to detect Cam - pylobacter spp. Most regions of the world are seeing an increase in campylobacter infections. The list of nationally notifiable diseases was expanded to include campylobacteriosis in 2015 [24]. However, due to the lack of a national surveillance programme and the irregular avail- ability of culture for Campylobacter species in clinical and research set- tings, the true frequency of Campylobacter spp. is still not adequately presented. After taking Trimethoprim for 48 hours, patients’ C-reactive protein levels (p=0.0042) and oxygen needs (p<0.021) were significant- ly lower in the Trimethoprim group than in the Recovery group. The oxygen requirement at Day 2 and Day 5 (p=0.039, p=0.002 respective- ly) compared to Day 0 was significantly improved in the Trimethoprim group but not in the Recovery group. Death was decreased (17% TMP against 36% for Recovery, p=0.022) although there were no appreciable variations in the need for invasive or non-invasive assistance. Trimetho- prim also shortened hospital stays; the average stay was 10 days, com- pared to 17 days for Recovery (p<0.0032). Trimethoprim’s immunological activities may be the reason for its observed benefits. Among these actions include the inhibition of the Formyl peptide receptors on the surface of circulating neutrophils and monocytes. These receptors play a role in both the neutrophils’ release of the “Reactive Oxygen Series,” which triggers a cytokine storm, and the phagocytes’ homing to the lung in response to inflammatory sig- nals. Trimethoprim’s blocking of these receptors will lessen neutrophil activation, soothe the host response, and lessen acute lung injury in Covid-19 cases. According to our findings, oral Trimethoprim lowered hospital stays and death while also reducing fevers, inflammatory indi- cators, and oxygen requirements more quickly. Keywords : Severe COVID-19; ARDS; Trimethoprim; Formyl peptide recep- tors; Recovery trial INTRODUCTION In 2020–2021, Covid-19 accounted for 66 million cases of adult respiratory distress syndrome globally, making it the most com- mon cause [1]. Many people with the condition recover on their own, but there are few effective treatments available for those who suffer severe respiratory failure [2-4]. According to data, 65–94% of patients hospitalised to critical care for mechanical ventilation died [5, 6]. The UK National Recovery study data demonstrated an 11% reduction in mortality for oxygen-depen- dent patients taking 6 mg of dexamethasone orally per day [7]. In contrast, there was a rise in mortality during the H1N1 influ- enza pandemic due to the usage of steroids [8]. Despite extensive research, adult respiratory distress syn- drome (ARDS) is a potentially fatal illness with few pharma- cological treatments [9, 10]. The lungs are subjected to a pro- longed neutrophil assault, which is fueled by the neutrophils’ continuous activation through their surface Formyl Peptide Receptors (FPR). One potential therapy strategy is to inhibit these receptors [11,12]. In response to Formyl Peptide Signals (FP) generated by bacteria and injured or dying cells, including mitochondrial DNA, neutrophils migrate to inflamed tissue. These FPs cause neutrophil surface FPRs to become more ac- www.directivepublications.org Page - 1 Journal of Digestive and Liver Diseases

Case Report tive, releasing oxidants that in turn cause alveolar cell damage and the production of cytokines [13, 14]. Although neutrophils are essential for fighting infection, tissue is poisoned when they infiltrate the lung. ARDS is caused by damage to the capillary endothelium, which results in alveolar oedema, decreased gas exchange, and fibroblast activation [15]. Neutrophils show up early in bronchoalveolar lavage samples from ARDS patients, and their quantity indicates the severity and prognosis of the condition. Acute lung injury is considerably reduced in animal models when neutrophil Formyl peptide receptors are geneti- cally deficient or depleted, indicating a critical function for this receptor [11,16]. Neutrophil NETosis can occur in highly activat- ed and stressed neutrophils that are being driven by an inten- sifying “cytokine storm.” In order to capture pathogens and cell debris, the neutrophil uses this process to extrude its DNA and chromatin into a “NET” (Neutrophil Extracellular Trap). According to postmortem studies in Covid-19 fatalities, these NETs might cause further tissue damage by blocking blood ves- sels, which are directly associated to the onset of ARDS and in- creased mortality [17, 18]. Numerous antibiotics have an impact on the immune system. Through blockade of the neutrophil surface Formyl peptide receptors, studies of the sulphonamide Dapsone (4, 4-diaminodiphenol sulphone) confirm its ability to reduce the generation of both intracellular and extracellular ox- ygen free radicals as well as proteases released by neutrophils in a dose-dependent manner [19–22]. In the UK, trimethoprim (TMP) is licenced to treat respiratory tract infections. TMP has the same ability to calm the host reaction as Dapsone, Cotrima- zole, Cyclosporin, and Hydroxychloroquine by blocking the sur- face Formyl Peptide receptor on neutrophils [19, 23]. Here, we provide our findings from treating oxygen-dependent patients with severe COVID-19 infection between April 2020 and April 2021 with trimethoprim added to normal therapy, and we com- pare the results with our patients who gave their agreement to be included in the National UK Recovery study for severe COVID-19. Method We have examined information from 130 patients with oxy- gen-dependent severe Covid-19 infection who were admitted to our ward between April 2020 and April 2021. The UK National Recovery study was open to all patients. These patients were admitted with symptoms for 10–16 days before to admission, including a rising temperature, cough, and dyspnea. They also had a positive Covid swab. On their initial chest X-ray, 85% of patients had bilateral lung infiltrates, and by five days of ad- mission, all patients had radiological alterations. Furthermore, pulmonary emboli were seen in the CT pulmonary angiogram of three individuals. According to the Trust guidelines, patients were started on routine antibiotic therapy, which included ox- ygen, heparin, and the antibiotics clarithromycin and benzyl penicillin to prevent bacterial super infection. phylaxis pro. One out of every four patients who were enrolled and randomly assigned to the recovery trial received further treatments; the other three patients served as the study’s standard therapy comparison arm [24]. Following patient discussion and verbal assent, trimethoprim (TMP) 200 mg 12 hours was added for 5 days in patients who were oxygen dependent and showing obvious signs of clinical deterioration if the Recovery study’s requirements were not completed or if the patient denied Re- covery enrollment.

Along with the 84 patients who enrolled in the recovery study, the clinical data for 46 TMP-treated patients who did not enter the research are also analysed. Following July 2020, oral dexa- methasone (6 mg) was added to regular Covid-19 medication for all patients. We report the results, which include the length of hospital stay, the progression to ventilatory support, the death rate, and the variations in C-reactive protein, body tem- perature, and oxygen consumption at days 0 through 5. “Day 0” denoted the start of the oral TMP or the day of enrollment in the Recovery trial. Every patient’s co-morbidities were noted. Patient Consent and Ethics The data is shown for patients who failed to receive admittance with verbal agreement to the addi- tion of TMP treatment, as well as for those who gave their con- sent to the Recovery trial. Their anonymised data will be used in this case series with their written agreement. Analytical Statistics The group means and standard error of the mean are displayed in the data. Mann Whitney made comparisons between the two patient groups. U test or Chi-square analysis for non-para- metric data, as shown in the tables. Between Days 0 and 5, the responses within each group were evaluated using a paired t test. It was significant at p= <0.05. PRISM 3.03 and SPSS were the statistical programmes utilised for the analysis. The tables displayed the analytical process. www.directivepublications.org Page - 2 Journal of Digestive and Liver Diseases

Case Report Results Case Series The patient groups and the 130 patients’ baseline characteris- tics are displayed in (Table 1). The two groups’ mean ages varied by 5 years, with the Recovery group’s mean age of 70 years and a higher proportion of male Caucasian patients. In comparison to the TMP group, the Recovery group had a greater co-morbid- ity for both hypertension and ischemic heart disease (p=0.022). Drugs for Recovery 1 Study 34 patients were enrolled in the Re- covery 1 trial, which ran from April to August 2020. Of these, 26 were randomised to continue receiving normal therapy, 2 to get additional Dexamethasone 6 mg/day, 4 to receive 400 mg/day of Hydroxychloroquine, and 2 to receive 200 mg of Lopinavir + 50 mg of Ritonavir at two tab-lets twice a day. These medica- tions were taken for ten days, or earlier if discharged earlier. Drug Study 2 Recoveries Recovery 2 study (September 2020–April 2021) enrolled 50 pa- tients, 35 of whom were randomised to continue receiving con- ventional therapy. Nine patients were given Aspirin 150 mg/day, two received Colchicine 500 mg twice a day, three received Azi- thromycin 500 mg/day, and one was given Baricitinib 4 mg twice a day. These medications were taken for ten days, or earlier if the patient was discharged. The results of the recovery research demonstrated that, in oxygen-dependent patients, dexametha- sone 6 mg/day reduced death by 11% and baricitinib reduced mortality by 2% in comparison to usual therapy. No additional Recovery trial medications demonstrated any efficacy [7,25]. Outcome Table 1 shows that 83% of TMP patients were discharged home compared to 64% in the Recovery group (p=0.010), and that 17% of the TMP patient group died (n=8) against 36% in the Recovery group (n=30). This difference was significant (p=0.014). The re- quirements for high flow nasal oxygen, mechanical ventilation, and continuous positive airway pressure did not differ signifi- cantly. For TMP and Recovery group, the average length of hos- pital stay was 10.6 days and 17.1 days, respectively (p=0.0032) (Table 1). According to the data, adding oral TMP may help pa- tients with severe COVID-19 experience less acute lung injury, which would shorten their hospital stay and lower their death rate as compared to the Recovery group. Nevertheless, these patients were not assigned at random to any group. TMP blocks the FPR, which may provide protection against worsening acute lung injury even if it has no direct antiviral ef- fects [19]. The advantage of TMP became evident within just 24 hours, most likely as a result of its efficient absorption, which by Day 2 and Day 5 considerably lowered the patients’ fever, inflammatory markers, and oxygen requirements—a reduction that the Recovery group of patients did not experience. This medication should lessen the likelihood of neutrophil NETosis and additional lung damage by reducing neutrophil migration to the lung and the release of oxidants and proteases with de- creased neutrophil activation [17–19]. Early detection of clinical deterioration is necessary for TMP treatment, since postponing treatment can decrease the drug’s effectiveness prior to neu- trophil blockage of the alveolar capillary bed. It is challenging to reverse NETosis. Although there are no official ARDS trials for TMP, case reports and circumstantial evidence point to the potential benefits of medications that block the FPR. The litera- ture does, in fact, contain data for rapidly progressive respira- tory failure in pulmonary fibrosis and Covid-19 infection, as well as dramatic case reports of rapid recovery from severe ARDS following the addition of intravenous cotrimoxazole (trimetho- prim+ sulphamethoxazole) in Middle Eastern Respiratory Syn- drome [28, 29]. In animal models, cyclosporin H, a particular FPR inhibitor, lessens acute lung injury when given either be- fore or after the lung insult. Alveolar protein leak and decreased alveolar neutrophil counts are linked to this medication. Cyclosporin A exhibits compara- ble effects, such as the capacity to lessen intracellular calcium influx, which is a crucial stage in the start of the NETosis cascade and suggests that FPR plays a functional role in signalling [30]. Targeting individual mediators later in the disease may not be as beneficial as suppressing the “out of control host” via their own neutrophils, as NETosis is a representation of later stages of ARDS. Conclusion ARDS is a potentially fatal illness for which there are now no reliable pharmacological treatments. It depicts a picture of a persistent neutrophil onslaught caused by a continuing neutro- phil-mediated immunological response. According to research on animals, the neutrophil Formyl Peptide Receptors may play a major role in this illness, and their inhibition may lessen both the immediate lung injury and the host response. Our research, which is corroborated by other data as discussed, demon- strates that oral TMP led to a quicker drop in fevers, inflamma- www.directivepublications.org Page - 3 Journal of Digestive and Liver Diseases

Case Report tory markers, and oxygen need along with a lower mean hos- pital stay and mortality. Larger groups of patients with severe Covid19 infections are needed to validate these observations so that the potential to save lives as well as the benefit to mortality and the need for ventilatory support can be properly evaluated. REFERENCES 1. WHO Coronavirus Disease (COVID-19) Dashboard. 2. Wilcox SR (2020) Management of respiratory failure due to covid-19. BMJ 369: m1786. 3. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hos- pital. 4. WHO (2020) Clinical management of COVID-19: interim guidance, World Health Organisation. 5. Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical pre- dictors of mortality due to 150 COVID-19 based on anal- ysis of 150 patients from Wuhan, China. Intensive Care Med 46(5): 846-848. 6. Zhou F, Yu T, Du R, Fan G, Lui G, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10299): 1054-1062. 7. Horby P, Shen Lim W, Emberson JR, Mafham M, Bell JL, et al. (2021) Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384(8): 693- 704. 8. Zhang Y, Sun W, Svendsen ER, Tang S, MacIntyre RC, et al. (2015) Do corticosteroids reduce the mortality of Influen- za A (H1N1) infection? A meta-analysis. Crit Care 19(46): 1-17. 9. Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Black- wood B, et al. (2019) Guidelines on the management of acute respiratory distress syndrome. BMJ open resp res 6(1): e000420. 10. Englert JA, Bobba C, Baron RM (2019) Integrating molec- ular patho- genesis and clinical translation in sepsis-in- duced acute respiratory dis- tress syndrome. JCI Insight 4(2): e124061. 11. Dorward DA, Lucas CD, Doherty MK, Chapman GB, Schole- field EJ, et al. (2017) Novel role for endogenous mitochon- drial formylated pep- tide-driven formyl peptide recep- tor-1 signalling in acute respiratory distress syndrome. Thorax 72(10): 928-936. 12. Li L, Chen K, Xianng Y, Yoshimura T, Su S, et al. (2016) New develop- ment in studies of formyl-peptide receptors: Critical roles in host de- fense. J Leukoc Biol 99(3): 425- 435. 13. Napolitano F, Rossi FW, Pesapane A, Varricchio S, Llardi G, et al. (2018) N-formyl peptide receptors induce radical oxygen production in fibro- blasts derived from systemic sclerosis by interacting with a cleaved form of urokinase receptor. Frontiers in Immunology 9: 574. 14. Weib E, Kretschmer D (2018) Formyl-peptide Receptors in infection, inflammation and Cancer. Trends in Immunolo- gy 39(10): 815-829. 15. Dorward DA, Lucus CD, Chapman GB, Haslett C, Dhali- wal A, et al. (2015) The role of Formylated peptides and Formyl peptide receptor-1 in governing neutrophil func- tion during acute inflammation. Amer- ican Journal of Pa- thology 185(5): 1172-1184. 16. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, et al. (2008) Ecto-nucleoside triphosphohydrolase 1 (E-NTP- Dase1/CD39) regulates neutrophil chemotaxis by hydro- lyzing released ATP to adenosine. J Biological Chemistry 283(42): 28480-28486. 17. Barnes BJ, Androver JM, Baxter-stoltzfus A, Borczuk A, Cools-Lartigue J, et al. (2020) Targeting Potential Drivers of COVID-19:Neutrophil Extracellular Traps. J Exp Med 217(6): e20200652. 18. Mozzini C, Girelli D (2020) The role of Neutrophil Extracel- lular traps in Covid-19: Only a hypothesis or a new field for research? Thrombosis research 191: 26-27. www.directivepublications.org Page - 4 Journal of Digestive and Liver Diseases

Case Report 19. Varney VA, Smith B, Quirke G, Parnell H, Rathneepan S, et al. (2017) The effects of oral cotrimoxazole upon neutro- phil and monocyte activa- tion in patients with pulmonary fibrosis and healthy controls; does this relate to its action in idiopathic pulmonary fibrosis? Thorax 72(3): 109. 20. Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: Inhibition of neutrophils adherence is associated with in- hibition of chemoattractant-induced signal transduction. J Leukocyte Biology 62(2): 827-836. 21. Wozel G, Blasum C (2014) Dapsone in dermatology and beyond. Arch Dermatol Res 306(2): 103-124. 22. Suda T, Suzuki Y, Matsui T, Inoue T, Nilde O, et al. (2005) Dapsone sup- presse human neutrophil superoxide pro- duction and elastase release in a calcium-dependant manner. Brit J Dermatol 152(5): 887-895. 23. Rubin BK, Tamaoki J (2005) Antibiotics as Anti-Inflam- matory and Immunomodulatory Agents. Basel; Boston: Birkhauser 273. 24. Wilkinson E (2020) Recovery Trial: the UK covid-19 study resetting expectations for clinical trials. British Medical Journal 369: m1626. 25. Horby PW, Landray MJ (2022) Baricitinib in patients ad- mitted with Covid 19 recovery: A randomised controlled open platform trial and updated meta-analysis. Lancet 400(10349): 349-368. 26. Yang AP, Liu J, Tao W, Li HM (2020) The diagnostic and pre- dictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharma- col 84: 106504. 27. Adams JY, Rogers AJ, Schuler A, Marelich GP, Fresco JM, et al. (2020) Association Between Peripheral Blood Oxy- gen Saturation (SpO2)/ Fraction of Inspired Oxygen (FiO2) Ratio Time at Risk and Hospital Mortality in Mechanically Ventilated Patients. Perm J 24(19): 113-120. 28. Moniri A, Marjani M, Tabarsi P, Yadegarynia D, Nadji SA (2015) Health Care Associated Middle East Respiratory Syn- drome (MERS): A Case from Iran. Tanaffos 14(4): 262-267. 29. Oda K, Yatera K, Ishimoto H, Nakao H, Hanaka T, Ogoshi T, et al. (2016) Efficacy of concurrent treatments in idiopathic pulmonary fi- brosis patients with rapidly progression of respiratory failure: an an- alysis of a national administra- tive database in Japan. BMC Pulmonary Medicine16(1): 91. 30. Wenzel-Seiferi K, Grunbaum L, Seifert R (1991) Differential inhibition of human neutrophil activation by cyclosporin A, D and H. Cyclo- sporin H is a potent and effective In- hibitor of formal peptide-induced superoxide formation. J Immunology 147(6): 1940-1946. 31. Arafat and Quadery. 2020 clinical trial protocol. Role of Co-trimoxazole in Severe COVID-19 Patients. https://clin- icaltrials.gov/ct2/show/ NCT04470531. 32. Quadery SR, Sinha P, Bhattacharjee M, Bose S, Ghosh UC, et al. (2022) Cotrimoxazole in hospitalised patients with severe Covid-19- interim results from CoTroxCov study. European Respiratory journal 60: 1544. 33. Singh S, Kumar P, John T (2021) Role of co-trimoxazole in patients with Covid-19 with acute respiratory failure re- quiring non-invasive ventila- tion: a single centre expe- rience. American journal of respiratory and critical care medicine 203: A2617. 34. Siddiqui KN, Das MK, Bandyopadhyay A (2020) Cotrimox- azole in the domiciliary management of patients with se- vere Covid-19: A case ser- ies. Journal of the Indian Medi- cal association 118(10): 34-38. 35. Al-Kuraisey HM, Al-Gareeb AI, Ai-Buhadily AK (2020) Cotri- moxazole and teicoplanin in the management of Covid-19: Pleiotrophic effects, shadows and lights. Curr Med Drug Res 4(2): 1-5. 36. Wise J (2022) Covid antiviral bought by UK does not lower risk of hos- pital admission. British Medical Journal 379: o2441. www.directivepublications.org Page - 5 Journal of Digestive and Liver Diseases

This is an automatically generated text version. For the formatted version of record, download the PDF →